In a filing, Terns Pharmaceuticals Inc revealed its 10% Owner Vivo Opportunity, LLC unloaded Company’s shares for reported $0.86 million on Apr 03 ’24. In the deal valued at $6.20 per share,138,066 shares were sold. As a result of this transaction, Vivo Opportunity, LLC now holds 268,573 shares worth roughly $1.46 million.
Then, Vivo Opportunity, LLC sold 101,480 shares, generating $674,842 in total proceeds. Upon selling the shares at $6.65, the 10% Owner now owns 272,722 shares.
Before that, Vivo Opportunity, LLC sold 181,117 shares. Terns Pharmaceuticals Inc shares valued at $1,266,008 were divested by the 10% Owner at a price of $6.99 per share. As a result of the transaction, Vivo Opportunity, LLC now holds 275,772 shares, worth roughly $1.5 million.
Mizuho initiated its Terns Pharmaceuticals Inc [TERN] rating to a Buy in a research note published on June 22, 2023; the price target was $16. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in early June with a ‘”a Buy”‘ rating. ROTH MKM began covering TERN with “Buy” recommendation on May 31, 2023. BMO Capital Markets started covering the stock on May 08, 2023. It rated TERN as “an Outperform”.
Price Performance Review of TERN
On Friday, Terns Pharmaceuticals Inc [NASDAQ:TERN] saw its stock jump 2.84% to $5.44. Over the last five days, the stock has gained 10.79%. Terns Pharmaceuticals Inc shares have fallen nearly -16.18% since the year began. Nevertheless, the stocks have fallen -57.83% over the past one year. While a 52-week high of $13.51 was reached on 03/07/24, a 52-week low of $3.26 was recorded on 04/19/24. SMA at 50 days reached $6.15, while 200 days put it at $5.82. A total of 0.56 million shares were traded, compared to the trading of 0.5 million shares in the previous session.
Levels Of Support And Resistance For TERN Stock
The 24-hour chart illustrates a support level at 5.24, which if violated will result in even more drops to 5.05. On the upside, there is a resistance level at 5.60. A further resistance level may holdings at 5.77. The Relative Strength Index (RSI) on the 14-day chart is 51.93, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.40, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 10.40%. Stochastics %K at 83.76% indicates the stock is a selling.
The most recent change occurred on February 14, 2023 when JMP Securities began covering the stock and recommended ‘”a Mkt outperform”‘ rating along with a $17 price target.
